Objective: To determine the effects of phosphodiesterase isoenzyme 5 (PDE5) inhibitors upon ureteropelvic junction obstruction (UPJO) in rabbits. Materials and Methods: Twenty-four New Zealand rabbits were randomly divided into three groups: sham-operated animals (group A; right-sided operations comprised subgroup A1 and left-sided operations comprised subgroup A2), operated animals (group B) and operated animals that received vardenafil (group C). The right-sided junctions of group A (A1) were not exposed, and therefore made up the control group. The UPJO model was established by partial obstruction of the left junction. Intravenous pyelograms were performed before and after the operation. HE staining and microscopic examinations were performed to chart the pathological changes. Immunohistochemistry (streptavidin peroxidase) was used to test the expression of TGF-β1 and nNOS in the junctions. RT-PCR detected mRNA expression of TGF-β1. Results: We observed serious hydronephrosis in group B and moderate hydronephrosis in group C, but not in group A. We also observed large pathological changes in group B, but little change in group C and no change in subgroups A1 and A2. The level of TGF-β1 in group B was significantly higher than in groups A and C; group C expressed more TGF-β1 than group A. More nNOS was detected in group C than group B, although the two groups both expressed nNOS at lower levels than group A. Conclusions: More TGF-β1 and less nNOS are expressed when the junction is obstructed. PDE5 inhibitors may be able to regulate these 2 factors, or other factors that have not been discussed in this experiment, in order to halt the progression of UPJO.

Keywords:
New Zealand rabbits, Phosphodiesterase isoenzyme 5 inhibitor, Ureteral obstruction, TGF-β1, nNOS
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.